How does triple-negative status influence your management of ET?
Is your management still guided primarily by risk stratification, or does the triple-negative status impact your decision-making about aspirin or cytoreduction?
1 Answer
Mednet MemberInvited Expert
Hematology · Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
Answered on
This is a fantastic question! First, I would ensure that the patient has triple negative ET (or pre-fibrotic PMF) and not a secondary cause for thrombocytosis. This requires a bone marrow biopsy and a careful examination with hematopathology to ensure there are morphologic features consistent with a...
Join for free or sign in to see the full answer